Literature DB >> 15726383

[Cyclosporine monitoring in patients with chronic uveitis].

S Schmidt1, U Pleyer.   

Abstract

BACKGROUND: Cyclosporine (CsA) is a widely used drug in the treatment of posterior uveitis. Whereas treatment with CsA has considerably improved the visual prognosis of uveitis patients, the therapeutic benefits of CsA are partially outweighed by its adverse effects, most notably nephrotoxicity and hypertension. Recently, monitoring the CsA 2-h postdose level (C(2)) has been recommended as the most sensitive assay and predictor of clinical outcome in transplantation. PATIENTS AND METHODS: This prospective clinical trial included 15 patients with posterior uveitis who received oral CsA (5 mg/kg BW b.i.d.). The relationship of C(2) to C0 blood levels was analyzed and correlated with clinical safety and efficacy.
RESULTS: A high intrapatient and interpatient variability was observed regarding the C0 values depending on several factors including comedication and intestinal resorption. C(2) values corresponded to control measurements of intraocular inflammation.
CONCLUSIONS: C(2) monitoring offers a simple and accurate alternative for clinical monitoring of CsA. It allows the dose of CsA to be individualized effectively for each patient.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15726383     DOI: 10.1007/s00347-005-1174-x

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  18 in total

1.  Population based assessment of uveitis in an urban population in southern India.

Authors:  L Dandona; R Dandona; R K John; C A McCarty; G N Rao
Journal:  Br J Ophthalmol       Date:  2000-07       Impact factor: 4.638

Review 2.  The possible impact of uveitis in blindness: a literature survey.

Authors:  M S Suttorp-Schulten; A Rothova
Journal:  Br J Ophthalmol       Date:  1996-09       Impact factor: 4.638

Review 3.  Individualization of cyclosporine therapy using pharmacokinetic and pharmacodynamic parameters.

Authors:  B D Kahan
Journal:  Transplantation       Date:  1985-11       Impact factor: 4.939

Review 4.  The pharmacokinetics of Sandimmun Neoral: a new oral formulation of cyclosporine.

Authors:  D W Holt; E A Mueller; J M Kovarik; J B van Bree; K Kutz
Journal:  Transplant Proc       Date:  1994-10       Impact factor: 1.066

5.  Comparison of several approaches of therapeutic drug monitoring of cyclosporin A based on individual pharmacokinetics.

Authors:  R Wacke; B Rohde; G Engel; G Kundt; E M Hehl; R Bast; H Seiter; B Drewelow
Journal:  Eur J Clin Pharmacol       Date:  2000-04       Impact factor: 2.953

6.  Reduced inter- and intrasubject variability in cyclosporine pharmacokinetics in renal transplant recipients treated with a microemulsion formulation in conjunction with fasting, low-fat meals, or high-fat meals.

Authors:  B D Kahan; J Dunn; C Fitts; D Van Buren; D Wombolt; R Pollak; R Carson; J W Alexander; M Choc; R Wong
Journal:  Transplantation       Date:  1995-02-27       Impact factor: 4.939

Review 7.  C2 monitoring of cyclosporine in de novo liver transplant recipients: the clinician's perspective.

Authors:  Federico Villamil; Stephen Pollard
Journal:  Liver Transpl       Date:  2004-05       Impact factor: 5.799

8.  Cyclosporine monitoring in stable, long-term, pediatric kidney transplant recipients: the value of C2 determination.

Authors:  M Ferraresso; L Ghio; S Tirelli; P Pedotti; E Taioli; A Edefonti; L Berardinelli
Journal:  Transplant Proc       Date:  2004-04       Impact factor: 1.066

9.  Clinical benefits of neoral C2 monitoring in the long-term management of renal transplant recipients.

Authors:  Edward Cole; Nava Maham; Carl Cardella; Daniel Cattran; Stanley Fenton; Jayne Hamel; Catherine O'Grady; Robert Smith
Journal:  Transplantation       Date:  2003-06-27       Impact factor: 4.939

10.  Cyclosporine therapy for uveitis: long-term followup.

Authors:  R B Nussenblatt; A G Palestine; C C Chan
Journal:  J Ocul Pharmacol       Date:  1985
View more
  1 in total

1.  [Intraocular inflammations. A diagnostic and therapeutic challenge].

Authors:  U Pleyer
Journal:  Ophthalmologe       Date:  2005-04       Impact factor: 1.059

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.